Taysha Gene Therapies (TSHA)
Advances TSHA-102, an AAV9 gene therapy in pivotal testing for Rett syndrome.
$5.28
After-hours close+0.13 (+2.45%)
At close$5.16(+2.28%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 92.12% | 300.17M shares | |
|---|---|---|---|
| 216 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 9.63% | 31.38M shares | |
| 7 holders · as of Jul 10, 2026 | |||
| Adds to | 101.75% | ||
325.83M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 101.75%; nothing is left for Other.
13F, as of Jun 30, 2026
216 holders · 300.17M shares · 45 new positions · 143 increased · 41 reduced · 25 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 23.89M | 7.33% | +2.19M | Aug 14, 2026 |
| Ra Capital Management, L.P. | 23.56M | 7.23% | 0 | Aug 14, 2026 |
| Goldman Sachs Group Inc | 22.71M | 6.97% | +343.5K | Aug 14, 2026 |
| BlackRock, Inc. | 20.69M | 6.35% | +2.33M | Aug 7, 2026 |
| Vestal Point Capital, LP | 19.42M | 5.96% | +1.42M | Aug 14, 2026 |
| Morgan Stanley | 16.49M | 5.06% | −1.48M | Aug 13, 2026 |
| RTW Investments, LP | 13.56M | 4.16% | −120.0K | Aug 14, 2026 |
| FMR LLC | 13.34M | 4.09% | −984.8K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLCincl. Behzad Aghazadeh | 9.99% | 23.09M | 13G | Nov 14, 2024 |
| RA Capital Management, L.P. | 9.90% | 27.66M | 13G | Nov 14, 2025 |
| Paul B Manningincl. The Paul B. Manning Revocable Trust dated May 10, 2000, The PBM 2023 Grantor Retained Annuity Trust +3 more | 9.80% | 25.60M | 13D | Jun 3, 2025 |
| RTW Investments, LP | 7.00% | 20.69M | 13G | May 15, 2026 |
| Morgan Stanley | 6.70% | 16.86M | 13G | Aug 6, 2025 |
| BlackRock, Inc. | 6.50% | 17.85M | 13G | Jan 21, 2026 |
| Vestal Point Capital, LP | 6.30% | 18.00M | 13G | May 15, 2026 |
| The Goldman Sachs Group, Inc. | 5.10% | 12.75M | 13G | Jul 3, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 10, 2026 | Sukumar Nagendrandirector, officer: President and Head of R&D | Sale | 200,000 | $6.24 | 936,410 |
| Apr 10, 2026 | Sukumar Nagendrandirector, officer: President and Head of R&D | Sale | 200,000 | $4.46 | 1,136,410 |
| Feb 4, 2026 | Kamran Alamofficer: CHIEF FINANCIAL OFFICER | Sale | 1,655 | $4.52 | 1,442,131 |
| Jan 26, 2026 | Kamran Alamofficer: CHIEF FINANCIAL OFFICER | Sale | 23,849 | $4.61 | 1,443,786 |
| Jan 23, 2026 | Kamran Alamofficer: CHIEF FINANCIAL OFFICER | Sale | 78,968 | $4.75 | 1,467,635 |
| Jan 26, 2026 | Sean P. Nolandirector, officer: Chief Executive Officer | Sale | 41,312 | $4.61 | 2,908,257 |
| Jan 23, 2026 | Sean P. Nolandirector, officer: Chief Executive Officer | Sale | 136,789 | $4.75 | 2,949,569 |
| Jan 26, 2026 | Sukumar Nagendrandirector, officer: President and Head of R&D | Sale | 26,918 | $4.61 | 1,317,389 |
| Jan 23, 2026 | Sukumar Nagendrandirector, officer: President and Head of R&D | Sale | 89,132 | $4.75 | 1,344,307 |
| Jan 12, 2026 | Sukumar Nagendrandirector, officer: President and Head of R&D | Sale | 200,000 | $4.71 | 1,006,439 |
House and Senate disclosures
Not reported.